DeepMed Research

Abramson Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pennmedicine.org

Clinical Trials

Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2008-07-14

Last Posted Date: 2016-02-18

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 38

Registration Number: NCT00714181

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer

Phase 1

Completed

Conditions: Ovarian Cancer
Peritoneal Cancer

Interventions: Biological: DCVac-L

First Posted Date: 2008-05-23

Last Posted Date: 2013-02-26

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 36

Registration Number: NCT00683241

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Study of Temzolomide and Gleevec in Advanced Melanoma

Phase 1

Terminated

Conditions: Melanoma
Advanced Melanoma

Interventions: Drug: Gleevec
Drug: Temodar

First Posted Date: 2008-04-28

Last Posted Date: 2023-03-30

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 32

Registration Number: NCT00667953

Locations: 🇺🇸
Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania, United States

Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Sorafenib + Docetaxel/Carboplatin

First Posted Date: 2008-03-31

Last Posted Date: 2019-10-22

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 7

Registration Number: NCT00647426

Locations: 🇺🇸
Abramson Cancer Center of University of Pennsylvania, Philadelphia, Pennsylvania, United States

Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia

Phase 2

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Bexarotene

First Posted Date: 2008-02-14

Last Posted Date: 2020-12-17

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 24

Registration Number: NCT00615784

Locations: 🇺🇸
Abramson Cancer Center of University of Pennsylvania, Philadelphia, Pennsylvania, United States

Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

Interventions: Drug: sorafenib tosylate
Drug: temozolomide

First Posted Date: 2008-01-28

Last Posted Date: 2022-06-14

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 169

Registration Number: NCT00602576

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura

Phase 2

Terminated

Conditions: Lung Cancer
Metastatic Cancer

Interventions: Drug: chemotherapy
Drug: porfimer sodium
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Procedure: spectroscopy
Procedure: therapeutic conventional surgery

First Posted Date: 2008-01-28

Last Posted Date: 2020-11-24

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 9

Registration Number: NCT00601848

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer

Phase 2

Terminated

Conditions: Colorectal Cancer

Interventions: Biological: bevacizumab
Drug: fluorouracil
Drug: leucovorin calcium
Drug: oxaliplatin

First Posted Date: 2008-01-28

Last Posted Date: 2020-04-28

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 5

Registration Number: NCT00602329

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Biological: bevacizumab
Drug: fluorouracil
Drug: gemcitabine hydrochloride
Drug: oxaliplatin
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Procedure: conventional surgery
Procedure: endoscopic biopsy
Procedure: laparoscopy
Radiation: radiation therapy

First Posted Date: 2008-01-28

Last Posted Date: 2020-04-27

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 19

Registration Number: NCT00602602

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Partial Breast Radiation Therapy in Treating Women Undergoing Breast Conservation Therapy for Early-Stage Breast Cancer

Not Applicable

Completed

Conditions: Long-term Effects Secondary to Cancer Therapy in Adults
Skin Reactions Secondary to Radiation Therapy
Breast Cancer

Interventions: Procedure: adjuvant therapy
Procedure: conventional surgery
Radiation: 3-dimensional conformal radiation therapy
Radiation: brachytherapy
Radiation: intracavitary balloon brachytherapy
Radiation: proton beam radiation therapy

First Posted Date: 2008-01-24

Last Posted Date: 2020-04-09

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 28

Registration Number: NCT00599989

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy